Neuphoria Therapeutics is leading the charge in transforming anxiety and PTSD treatment with BNC 210, a groundbreaking drug designed to reduce anxiety within 60 minutes without sedation or habit formation. Hear from Spyros Papapetropoulos MD, PhD, President and CEO of Neuphoria Therapeutics, as he shares the company’s vision and innovative approach to shaping the future of mental health care.
Video by Adriana Kaegi
Comments